CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,545	$ 298,172
Short-term marketable securities	62,881	29,312
Receivables from collaborative arrangements	17,474	16,785
Prepaid clinical and development services	2,038	1,513
Other prepaid and current assets	11,603	7,682
Total current assets	133,541	353,464
Property and equipment, net	9,068	11,875
Operating lease assets	36,287	40,126
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	8,067	6,899
Total assets	381,999	607,400
Current liabilities:
Accounts payable	1,524	1,554
Accrued personnel-related expenses	6,443	10,314
Accrued clinical and development expenses	2,246	4,932
Accrued general and administrative expenses	2,900	4,020
Operating lease liabilities	3,923	6,753
Tenant improvement payable to subleasee	6,490
Other accrued liabilities	1,241	1,142
Total current liabilities	24,767	28,715
Long-term operating lease liabilities	45,236	45,407
Future royalty payment contingency	27,788	25,438
Long-term deferred revenue		192
Unrecognized tax benefits	65,294	64,191
Other long-term liabilities	5,919	1,657
Commitments and contingencies
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 48,091 and 65,227 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively		1
Additional paid-in capital	1,122,164	1,295,725
Accumulated other comprehensive loss	(65)	(15)
Accumulated deficit	(909,104)	(853,911)
Total shareholders' equity	212,995	441,800
Total liabilities and shareholders' equity	$ 381,999	$ 607,400